乾性角結膜炎(ドライアイ)治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0963
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年3月31日
◆ページ数:320
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis Sicca – Pipeline Review, H1 2020, provides an overview of the Keratoconjunctivitis Sicca (Ophthalmology) pipeline landscape.

Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) is a condition in which a person experience desiccation of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues and immunosuppressants.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis Sicca – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratoconjunctivitis Sicca (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis Sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 17, 29, 7, 1, 38, 6 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 1 molecules, respectively.

Keratoconjunctivitis Sicca (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis Sicca (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis Sicca (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keratoconjunctivitis Sicca (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keratoconjunctivitis Sicca (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis Sicca (Ophthalmology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis Sicca (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis Sicca (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Keratoconjunctivitis Sicca (Dry Eye) – Overview
Keratoconjunctivitis Sicca (Dry Eye) – Therapeutics Development
Keratoconjunctivitis Sicca (Dry Eye) – Therapeutics Assessment
Keratoconjunctivitis Sicca (Dry Eye) – Companies Involved in Therapeutics Development
Keratoconjunctivitis Sicca (Dry Eye) – Drug Profiles
Keratoconjunctivitis Sicca (Dry Eye) – Dormant Projects
Keratoconjunctivitis Sicca (Dry Eye) – Discontinued Products
Keratoconjunctivitis Sicca (Dry Eye) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by AB2 Bio Ltd, H1 2020
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Abilita Bio Inc, H1 2020
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Actinobac Biomed Inc, H1 2020
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Aerie Pharmaceuticals Inc, H1 2020
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Aldeyra Therapeutics Inc, H1 2020
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Allegro Ophthalmics LLC, H1 2020
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Allergan Plc, H1 2020
Keratoconjunctivitis Sicca (Dry Eye) - Dormant Projects, H1 2020
Keratoconjunctivitis Sicca (Dry Eye) - Discontinued Products, H1 2020

【掲載企業】

AB2 Bio Ltd
Abilita Bio Inc
Actinobac Biomed Inc
Aerie Pharmaceuticals Inc
Aldeyra Therapeutics Inc
Allegro Ophthalmics LLC
Allergan Plc
Allgenesis Biotherapeutics Inc
Allosterix Ltd
Allysta Pharmaceuticals Inc
Apidel SA
Ascendia Pharmaceuticals LLC
Aurinia Pharmaceuticals Inc
Aviara Pharmaceuticals Inc
AxeroVision Inc
Azura Ophthalmics Ltd
Bessor Pharma LLC
BRIM Biotechnology Inc
Cambium Medical Technologies LLC
Cellix Bio Pvt Ltd
Dhp Korea Ltd
Dompe Farmaceutici SpA
Emerald Bioscience Inc
EyGen Ltd
GL Pharm Tech Corp
Glaukos Corp
Glia LLC
HanAll Biopharma Co Ltd
Huons Co Ltd
Huons Global Co Ltd
Icure Pharmaceutical Inc
Ipsen SA
IVIEW Therapeutics Inc
Kala Pharmaceuticals Inc
Kowa Co Ltd
Kukje Pharmaceutical Industry Co Ltd
Kv1.3 Therapeutics
Laboratoires Thea SA
Laboratorios Sophia SA de CV
Lee's Pharmaceutical Holdings Ltd
LTT Bio-Pharma Co Ltd
Lubris Biopharma
Marinomed Biotech AG
MC2 Therapeutics AS
Merck & Co Inc
Mimetogen Pharmaceuticals Inc
Mitotech SA
MyX Therapeutics Inc
Nanomerics Ltd
Neuroptika Inc
Novaliq GmbH
Novartis AG
Noveome Biotherapeutics Inc
OccuRx Pty Ltd
Ocugen Inc
Ocular Therapeutix Inc
Oculis SA
Ocunova LLC
OKYO Pharma Ltd
OncoNOx ApS
Oyster Point Pharma Inc
Palatin Technologies Inc
Panag Pharma Inc
Panoptes Pharma GesmbH
Pharmaleads SA
Pleryon Therapeutics Ltd
Proteris Biotech Inc
Quorum Innovations LLC
Redwood Pharma AB
RegeneRx Biopharmaceuticals Inc
RHNanopharmacuticals LLC
RiniSight Inc
Samjin Pharm Co Ltd
Senju Pharmaceutical Co Ltd
Serentrix LLC
Silk Technologies Ltd
Stuart Therapeutics Inc
Surface Pharmaceuticals Inc
Sylentis SAU
Tarsius Pharma Ltd
TearSolutions LLC
Tetra Bio-Pharma Inc
TopiVert Ltd
Vanda Pharmaceuticals Inc
Xigen SA
Yuyu Pharma Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[乾性角結膜炎(ドライアイ)治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆